AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00508872
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
Trial: NCT00993382
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake
Trial: NCT00411892
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, inhalation.
Trial: NCT01841411
Drug: Metronidazole + N-Acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
Trial: NCT01256424
Drug: HAL 5% with illumination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
Trial: NCT01256424
Drug: HAL 1% with illumination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
Trial: NCT01256424
Drug: HAL 0.2% with illumination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
Trial: NCT01256424
Drug: Placebo ointment without illumination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a singe dose of 2g placebo ointment, no photoactivation
Trial: NCT01907854
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin placebo tablets once-daily
Trial: NCT02851277
Drug: ASP0892 Intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection
Trial: NCT02851277
Drug: ASP0892 Intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT02851277
Drug: Placebo Intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection
Trial: NCT02851277
Drug: Placebo Intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT00807911
Drug: Adjuvant FL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
Trial: NCT00807911
Drug: Adjuvant FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
Trial: NCT00821795
Drug: NPH/Regular 70/30 mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
Trial: NCT04277897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Hepenofovir Fumarate Tablets
Trial: NCT01151865
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
Trial: NCT00004169
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00589823
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
Trial: NCT00790595
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
Trial: NCT00790595
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
Trial: NCT00790595
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
Trial: NCT00790595
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
Trial: NCT00790595
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
Trial: NCT04130633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vapor (distilled water)
Trial: NCT01493791
Drug: CDB-2914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01253837
Drug: L19TNFa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles.
Trial: NCT03219723
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (potency)
Trial: NCT00525499
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle control applied topically twice daily for 12 weeks
Trial: NCT03939429
Drug: QPX2015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT03939429
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01939236
Drug: Placebo (gummeline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days.
Trial: NCT02425774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02796170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg pill taken once daily- placebo of Dapagliflozin
Trial: NCT02213627
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01614886
Drug: ENA713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
Trial: NCT02213627
Drug: HP-hMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03149562
Drug: plasma transfusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These critical ill neonates with plasma transfusions
Trial: NCT03149562
Drug: non-plasma transfusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These critical ill neonates without plasma transfusions
Trial: NCT03755310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent dosage, route of administration and dose regimen
Trial: NCT01589185
Drug: KBSA301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
Trial: NCT00260533
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (matching to atomoxetine)
Trial: NCT01589185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a single intravenous infusion
Trial: NCT04493255
Drug: [14C]E7090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]E7090, oral capsule.
Trial: NCT01761877
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02266511
Drug: Flomax®, Norman II facility
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02266511
Drug: Flomax®, Nishine facility
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01356615
Drug: low molecular weight heparin (enoxaparin sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
Trial: NCT02558296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet to match active comparator
Trial: NCT02989597
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative pain medication
Trial: NCT02989597
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative pain medication
Trial: NCT01356615
Drug: standard unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
Trial: NCT02868632
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-L1 human monoclonal antibody
Trial: NCT03219372
Drug: Pravastatin Pill
RxNorm normalized name: pravastatin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: statin
Trial: NCT03219372
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00686413
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral
Trial: NCT00533117
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
Trial: NCT01263197
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT01263197
Drug: placebo for LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT02700906
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
Trial: NCT02837770
Drug: Diclofenac Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
Trial: NCT02837770
Drug: Pacebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacebo pill will be administered 4 hours before the IVI.
Trial: NCT02837770
Drug: Oral Diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
Trial: NCT01773044
Drug: Placebo (for alcalinized lidocaine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01211210
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Trial: NCT01211210
Drug: fluorouracil, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Trial: NCT01211210
Drug: fluorouracil, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
Trial: NCT00752063
Drug: Sorafenib with Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
Trial: NCT03818321
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
Trial: NCT01403532
Drug: Traditional intervention for HH using HCG and FSH
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
Trial: NCT01403532
Drug: Sequential intervention for HH using HCG and FSH
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
Trial: NCT01403532
Drug: Sequential intervention for HH using HCG and FSH plus zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
Trial: NCT00106704
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet once daily for 24 weeks
Trial: NCT03183297
Drug: JMI-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMI-001, a combination product of naproxen and fexofenadine
Trial: NCT03183297
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 220mg
Trial: NCT03183297
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT01107054
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of non-matched placebo on Day 4.
Trial: NCT01995838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Trial: NCT03516630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drops
Trial: NCT00403520
Drug: Experimental 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Donepezil Hydrochloride 10 mg orally for 12 months
Trial: NCT00403520
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Matching placebo orally for 12 months
Trial: NCT01848769
Drug: CHF1535 pMDI + AC Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four inhalations for a total dose of BDP/FF 200/24 mcg
Trial: NCT01848769
Drug: BDP + AC Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four inhalations for a total dose of BDP 200 mcg
Trial: NCT00571493
Drug: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells.
Trial: NCT01249261
Drug: Placebo/Risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
Trial: NCT01743222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node
Trial: NCT02512783
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Trial: NCT01049360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
Trial: NCT03114683
Drug: PD1
RxNorm normalized name: STATLOCK UNIVERSAL PLUS LG VUPD1214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI308 200mg/3 weeks
Trial: NCT01572129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to the chronic daily dose of 75 mg
Trial: NCT04467684
Drug: CB-0406 100 mg
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04467684
Drug: CB-0406 200 mg
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04467684
Drug: CB-0406 400 mg
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04467684
Drug: CB-0406 800 mg
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04467684
Drug: CB-0406 1,000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04467684
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Color and size matched placebo
Trial: NCT00023660
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023660
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02473341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated.
Trial: NCT03247140
Drug: JLP-1401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Trial: NCT03247140
Drug: Telmisartan/Amlodipine, Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Trial: NCT03158532
Drug: Placebo I
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Trial: NCT03158532
Drug: Placebo II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Trial: NCT03526848
Drug: 3BNC117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3BNC117
Trial: NCT03603626
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hour before surgery
Trial: NCT01967940
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet administered orally once daily with food
Trial: NCT01967940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to match TAF administered orally once daily with food
Trial: NCT01967940
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg STR administered orally once daily with food
Trial: NCT01967940
Drug: Current failing ARV regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue taking their current ARV regimen as prescribed in Part 1.
Trial: NCT01419964
Drug: Group 01
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH24
Trial: NCT01419964
Drug: Group 02
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00870740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC injection
Trial: NCT02015260
Drug: Topical NO
RxNorm normalized name: thickening agent, topical no.1 TOPICAL LIQUID (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varying doses of sodium nitrite and citric acid co-applied to warts
Trial: NCT02015260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01882166
Drug: fostimon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05129644
Drug: P1101 (24 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
Trial: NCT05129644
Drug: P1101 (48 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
Trial: NCT05129644
Drug: P1101 (90 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
Trial: NCT05129644
Drug: P1101 (180 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
Trial: NCT05129644
Drug: P1101 (225 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.